呼吸器感染症の原因となる臨床分離菌に対するgemifloxacinの抗菌力

書誌事項

タイトル別名
  • Antibacterial activity of gemifloxacin against clinical isolates

この論文をさがす

抄録

In vitro antibacterial activity of gemifloxacin, a new fluoro quinolone agent, and other drugs was determined against clinical isolates in 2005 Japan and clinical isolates of levofloxacin-resistant Streptococcus pneumoniae after 2003.<BR>Gemifloxacin MIC90 was 0.031μg/mL, higher than other fluoro quinolone agents. Gemifloxacin activity is good in levofloxacin-resistant S. pneumoniae because gemifloxacin MIC90 of levofloxacin-resistant Streptococcus pneumoniae was 0.5μg/mL, higher than other fluoro quinolone agents. Gemifloxacin MIC90 against Haernophilus influenzae was 0.015μg/mL. Gemifloxacin MIC90 against ampicillin-resistant β-lactamase negative Haemophilus influenzae (BLNAR) was 0.063μg/mle. Gemifloxacin MIC90 against methicillin-resistant Staphylococcus aureus was low the same as for other fluoro quinolone agents. Gemifloxacin activity was shown in Moraxella (Branhamella) catarrhalis, Kiebsiella pneumoniae, and Pseudomonas aeruginosa similar to other fluoro-quinolone agents. Our results suggest that gemifloxacin effective clinical respiratory organ infectious disease treatment.

収録刊行物

参考文献 (11)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ